A study has shown that in oxazolone (OXZ)-induced Th2-type colitis, the cholinergic anti-inflammatory pathway inhibits Rac1 activity and eventual Rac1 inactivation of the colitis through the α7 nicotinic acetylcholine receptor (α7nAChR) on pDCs, which prevents pDCs migration toward the inflammation site [54]. This evidence concerns the gene RAC1 and colitis.